Billionaire Profile
P
Global Rank
#602

Image: Unknown Author | Public domain | via Wikimedia Commons

Philipp Boehringer

CEO, Pharmaceuticals
GERMANY
Real-Time Net Worth
$6.636B
Estimated based on Pharmaceuticals stock value as of April 20, 2026
0% (24h)
Age
47
Source
Pharmaceuticals
Industry
Healthcare
Citizenship
GERMANY

Biography

Philipp Boehringer, a prominent figure in the pharmaceutical industry, is estimated to have a net worth of $6.6 billion, derived from his family's ownership of Boehringer Ingelheim, a leading private pharmaceutical company. At 47 years old, Philipp is a key member of the Boehringer family, which has been instrumental in the company's success since its founding in 1885. His career is intrinsically linked to Boehringer Ingelheim, where he likely plays a significant role in the company's strategic direction and innovation. The company's focus on pharmaceuticals and its commitment to research and development have been central to the family's enduring wealth and impact on global healthcare.

Fact Checked
Verified by Editorial Team
Live Data
Updated 4/20/2026

Wealth Over Time

In-Depth Profile

Early Life

While specific details about Philipp Boehringer's early life are not widely available in public sources, it is known that he is part of the Boehringer family, the owners of Boehringer Ingelheim. The company was founded in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany. Philipp is likely a descendant of the founding family and has grown up within a legacy of pharmaceutical innovation.

Rise to Success

Philipp Boehringer's success is directly linked to Boehringer Ingelheim. The company is the world's largest private pharmaceutical company, with a global presence and over 54,000 employees. The family ownership structure has allowed the company to focus on long-term goals and significant reinvestment in research and development, a key factor in its sustained growth and wealth. Philipp, along with 14 other family members, holds equal parts of the company.

Key Business Strategies

Boehringer Ingelheim's key business strategies include a strong focus on research and development, particularly in areas like cardiovascular, renal, and metabolic diseases, oncology, and respiratory diseases. The company has invested approximately €6.2 billion in R&D in 2024, which represents 23.2% of consolidated net sales. The company is also expanding and renewing its product portfolio to secure long-term growth and launching new treatments. Moreover, the company emphasizes strategic partnerships to drive innovation and expand its market reach.

Philanthropy

While specific details about Philipp Boehringer's personal philanthropic endeavors are not readily available, Boehringer Ingelheim is committed to several initiatives, including the Boehringer Ingelheim Cares Foundation. The company is also involved in various partnerships and collaborations to advance healthcare and improve the well-being of both humans and animals.

Philanthropy & Social Impact

Healthcare

Boehringer Ingelheim Cares Foundation

Information not available

The foundation supports various healthcare initiatives.

Controversies & Challenges

2023

Price Fixing

Boehringer Ingelheim was ordered to pay a 10 million Euro fine for illegal price fixing that had gone on globally over a period of nearly fifteen years.